Editorial: Novel preclinical model, biomarker, treatment and drug delivery to address immune evasion in cancer.
作者信息
Mai Chun-Wai, Macek Jilkova Zuzana, Dua Kamal, Goh Bey-Hing
机构信息
Faculty of Pharmaceutical Sciences, UCSI University, Kuala Lumpur, Malaysia.
Univ. Grenoble Alpes, INSERM U 1209, CNRS UMR 5309, Institute for Advanced Biosciences, Grenoble, France.
出版信息
Front Immunol. 2024 Sep 13;15:1486819. doi: 10.3389/fimmu.2024.1486819. eCollection 2024.
Abstract
摘要
相似文献
1
Editorial: Novel preclinical model, biomarker, treatment and drug delivery to address immune evasion in cancer.社论：用于解决癌症免疫逃逸问题的新型临床前模型、生物标志物、治疗方法及药物递送
Front Immunol. 2024 Sep 13;15:1486819. doi: 10.3389/fimmu.2024.1486819. eCollection 2024.
2
Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion.EMT 与 PD-L1 信号转导之间的通讯：肿瘤免疫逃逸的新见解。
Cancer Lett. 2020 Jan 1;468:72-81. doi: 10.1016/j.canlet.2019.10.013. Epub 2019 Oct 9.
3
Mechanisms of immune escape in the cancer immune cycle.癌症免疫周期中的免疫逃逸机制。
Int Immunopharmacol. 2020 Sep;86:106700. doi: 10.1016/j.intimp.2020.106700. Epub 2020 Jun 23.
4
How Tumor Cell Dedifferentiation Drives Immune Evasion and Resistance to Immunotherapy.肿瘤细胞去分化如何驱动免疫逃逸和对免疫治疗的抵抗。
Cancer Res. 2020 Oct 1;80(19):4037-4041. doi: 10.1158/0008-5472.CAN-20-1420. Epub 2020 Jun 18.
5
Acquired resistance to cancer immunotherapy.获得性癌症免疫疗法耐药性。
Semin Immunopathol. 2019 Jan;41(1):31-40. doi: 10.1007/s00281-018-0692-y. Epub 2018 Jul 2.
6
Translational Control of Immune Evasion in Cancer.癌症中免疫逃逸的转译控制。
Trends Cancer. 2021 Jul;7(7):580-582. doi: 10.1016/j.trecan.2021.04.002. Epub 2021 May 7.
7
Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy.社论：靶向吲哚胺2,3-双加氧酶和色氨酸双加氧酶用于癌症免疫治疗
Front Immunol. 2021 Dec 6;12:789473. doi: 10.3389/fimmu.2021.789473. eCollection 2021.
8
Cross-Talks between Raf Kinase Inhibitor Protein and Programmed Cell Death Ligand 1 Expressions in Cancer: Role in Immune Evasion and Therapeutic Implications.Raf 激酶抑制剂蛋白与程序性细胞死亡配体 1 表达在癌症中的串扰：在免疫逃逸中的作用和治疗意义。
Cells. 2024 May 17;13(10):864. doi: 10.3390/cells13100864.
9
Editorial: Understanding convergent evasion mechanisms in cancer and chronic infection: implications for immunotherapy.社论：理解癌症和慢性感染中的趋同逃逸机制：对免疫治疗的启示
Front Immunol. 2024 Jul 1;15:1450555. doi: 10.3389/fimmu.2024.1450555. eCollection 2024.
10
Tumor resistance to specific lysis: a major hurdle for successful immunotherapy of cancer.肿瘤对特异性裂解的抗性：癌症成功免疫治疗的主要障碍。
Clin Immunol. 2009 Jan;130(1):34-40. doi: 10.1016/j.clim.2008.08.020. Epub 2008 Nov 13.
本文引用的文献
1
The association between tumour heterogeneity and immune evasion mechanisms in hepatocellular carcinoma and its clinical implications.肝细胞癌中肿瘤异质性与免疫逃逸机制的关联及其临床意义。
Br J Cancer. 2024 Aug;131(3):420-429. doi: 10.1038/s41416-024-02684-w. Epub 2024 May 17.
2
Precision medicine in nasopharyngeal carcinoma: comprehensive review of past, present, and future prospect.鼻咽癌精准医学：过去、现在和未来展望的全面综述。
J Transl Med. 2023 Nov 6;21(1):786. doi: 10.1186/s12967-023-04673-8.
3
Targeting the crosstalk of epigenetic modifications and immune evasion in nasopharyngeal cancer.靶向鼻咽癌中表观遗传修饰和免疫逃逸的串扰。
Cell Biol Toxicol. 2023 Dec;39(6):2501-2526. doi: 10.1007/s10565-023-09830-9. Epub 2023 Sep 27.
4
Modeling prostate cancer: What does it take to build an ideal tumor model?建立前列腺癌模型：构建理想肿瘤模型需要什么？
Cancer Lett. 2022 Sep 1;543:215794. doi: 10.1016/j.canlet.2022.215794. Epub 2022 Jun 17.
5
Molecular Mechanisms and Potential Therapeutic Reversal of Pancreatic Cancer-Induced Immune Evasion.胰腺癌诱导免疫逃逸的分子机制及潜在治疗逆转
Cancers (Basel). 2020 Jul 11;12(7):1872. doi: 10.3390/cancers12071872.
Zotero 插件